Akero Therapeutics (AKRO) BidaskScore is downgraded to Strongly Sold

Akero Therapeutics, Inc.

The BidaskScore of Akero Therapeutics Inc. AKROAKRO shows that the shares of the company are now AKROStrongly Bought Strongly Sold by investors.

The BidaskScore of the PharmaceuticalsPharmaceuticals shows that the sector is PharmaceuticalsStrongly Bought Strongly Sold since October 1.

Here are the BidAskScore of other related companies in the Pharmaceuticals sector:

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Akero Therapeutics, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.